Concert Pharmaceuticals, Inc. (CNCE): Price and Financial Metrics

Concert Pharmaceuticals, Inc. (CNCE): $8.37

0.01 (+0.12%)

POWR Rating

Component Grades








Add CNCE to Watchlist
Sign Up

Industry: Biotech




#216 of 400

in industry

CNCE Price/Volume Stats

Current price $8.37 52-week high $8.55
Prev. close $8.36 52-week low $2.66
Day low $8.35 Volume 10,733,200
Day high $8.55 Avg. volume 2,970,800
50-day MA $7.49 Dividend yield N/A
200-day MA $5.99 Market Cap 401.24M

CNCE Stock Price Chart Interactive Chart >

Concert Pharmaceuticals, Inc. (CNCE) Company Bio

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform (deuterated chemical entity platform) to create novel small molecule drugs. The company was founded in 2006 and is based in Lexington, Massachusetts.

CNCE Latest News Stream

Event/Time News Detail
Loading, please wait...

CNCE Latest Social Stream

Loading social stream, please wait...

View Full CNCE Social Stream

Latest CNCE News From Around the Web

Below are the latest news stories about CONCERT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CNCE as an investment opportunity.

Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

LEXINGTON, Mass., February 15, 2023--Concert maintains deuruxolitinib breakthrough therapy designation from FDA for the treatment of alopecia areata.

Yahoo | February 15, 2023

Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer

Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week.

Yahoo | January 23, 2023

5 big deal reports: Sun Pharma’s $576M pact for Concert Pharma

By Davit Kirakosyan

Yahoo | January 22, 2023

Why Concert Pharmaceuticals Stock Rocketed Higher This Week

If all goes according to plan, Concert Pharmaceuticals (NASDAQ: CNCE) will soon cease to be an independent company. The biotech signed a deal to be acquired by a peer; as a result, its share price leaped more than 17% higher on the week, according to data compiled by S&P Global Market Intelligence. The two companies didn't hesitate to point out that this is roughly 33% higher than the latter's 30-day-trailing weighted average share price as of Wednesday, Jan. 18.

Yahoo | January 20, 2023

We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. Indeed, Concert Pharmaceuticals...

Yahoo | January 20, 2023

Read More 'CNCE' Stories Here

CNCE Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 24.93%
3-year -14.77%
5-year -42.04%
YTD 43.32%
2022 85.40%
2021 -75.08%
2020 37.02%
2019 -26.49%
2018 -51.49%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!